Brief: Gensight Biologics Announces Publication Of LUMEVOQ Safety Data

Gensight Biologics SA

09/03/2023 06:38

March 9 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * ANNOUNCES PUBLICATION OF LUMEVOQ SAFETY DATA OVER 5-YEAR
PERIOD
IN PEER-REVIEWED AMERICAN JOURNAL OF OPHTHALMOLOGY
    * POOLED ANALYSIS OF SAFETY DATA FROM 5 CLINICAL STUDIES IN
189
PATIENTS CONSTITUTING LARGEST EVER ND4-LHON COHORT TREATED WITH
GENE THERAPY
    * COMPARABLE SAFETY OUTCOMES AMONG BILATERALLY TREATED
PATIENTS
AND THOSE RECEIVING ONE UNILATERAL INJECTION
    * CONFIRMATION OF LONG-TERM SAFETY PROFILE OF INTRAVITREAL
INJECTIONS OF LUMEVOQ WITH 5-YEAR PERIOD DATA AFTER
ADMINISTRATION

Source text for Eikon:  ID:nBw618G5ya 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;;))